Glycolysis Metabolism in Neurodegeneration

Glycolysis Metabolism in Neurodegeneration

Introduction

Glycolysis Metabolism in Neurodegeneration is a critical component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@cunnane2020]

Brain glucose metabolism is essential for neuronal function, with glycolysis providing rapid energy and metabolic intermediates. Cerebral glucose hypometabolism is an early hallmark of Alzheimer's disease and contributes to other neurodegenerative conditions. [@mergenthaler2013]

Overview

The glycolytic pathway converts glucose to pyruvate: [@pellerin1994]

• Input: Glucose
• Output: Pyruvate, ATP, NADH
• Location: Cytoplasm of all cells

Key Enzymes

| Enzyme | Step | Regulation | [@mosconi2008]
|--------|------|------------| [@hertz2015]
| Hexokinase (HK) | Glucose → G6P | Inhibited by G6P | [@camandola2017]
| Phosphofructokinase (PFK) | F6P → F1,6BP | AMP/ATP, citrate | [@zhou2015]
| Pyruvate kinase (PK) | PEP → Pyruvate | Allosteric activation | [@arnold2018]

Brain Energy Metabolism

• Glucose uptake: GLUT1 (BBB), GLUT3 (neurons)
• Astrocyte-neuron lactate shuttle: Critical for neurotransmission
• Alternative fuels: Ketone bodies, lactate

Glycolytic Pathway

The Complete Pathway

Molecular Mechanisms

1. Cerebral Glucose Hypometabolism

...

Glycolysis Metabolism in Neurodegeneration

Introduction

Glycolysis Metabolism in Neurodegeneration is a critical component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@cunnane2020]

Brain glucose metabolism is essential for neuronal function, with glycolysis providing rapid energy and metabolic intermediates. Cerebral glucose hypometabolism is an early hallmark of Alzheimer's disease and contributes to other neurodegenerative conditions. [@mergenthaler2013]

Overview

The glycolytic pathway converts glucose to pyruvate: [@pellerin1994]

• Input: Glucose
• Output: Pyruvate, ATP, NADH
• Location: Cytoplasm of all cells

Key Enzymes

| Enzyme | Step | Regulation | [@mosconi2008]
|--------|------|------------| [@hertz2015]
| Hexokinase (HK) | Glucose → G6P | Inhibited by G6P | [@camandola2017]
| Phosphofructokinase (PFK) | F6P → F1,6BP | AMP/ATP, citrate | [@zhou2015]
| Pyruvate kinase (PK) | PEP → Pyruvate | Allosteric activation | [@arnold2018]

Brain Energy Metabolism

• Glucose uptake: GLUT1 (BBB), GLUT3 (neurons)
• Astrocyte-neuron lactate shuttle: Critical for neurotransmission
• Alternative fuels: Ketone bodies, lactate

Glycolytic Pathway

The Complete Pathway

Molecular Mechanisms

1. Cerebral Glucose Hypometabolism

| Change | Effect | [@schn2019]
|--------|--------| [@yao2011]
| ↓ GLUT1/3 | Reduced glucose uptake |
| ↓ PFK activity | Impaired glycolysis |
| ↓ PDH activity | Reduced acetyl-CoA |
| ↓ Mitochondrial function | Energy failure |

2. Astrocyte-Neuron Lactate Shuttle (ANLS)

3. Metabolic Dysfunction Cascade

Alzheimer's Disease

Key Findings in AD

| Finding | Brain Region | Diagnostic Use |
|---------|--------------|----------------|
| ↓ Glucose metabolism | Posterior cingulate, parietal | FDG-PET biomarker |
| ↓ PFK activity | Cortex, hippocampus | Research |
| ↓ GLUT1/3 | BBB, neurons | Pathology |
| ↑ Lactate | CSF, brain tissue | Biomarker |

Mechanisms

• Amyloid interaction: Aβ inhibits PFK
• [Tau pathology: Affects glucose transporters
• Vascular contributions: CBF reduction
• Insulin resistance: Type 3 diabetes hypothesis

Therapeutic Implications

| Target | Approach | Status |
|--------|----------|--------|
| GLUT1 | Increase expression | Preclinical |
| PFK activators | Enhance glycolysis | Research |
| Insulin signaling | Intranasal insulin | Clinical trials |
| Ketogenic diet | Alternative fuel | Clinical trials |

Parkinson's Disease

Metabolic Changes in PD

• Basal ganglia: Reduced glucose metabolism
• Substantia nigra: Mitochondrial complex I deficiency
• Widespread: White matter hypometabolism

Mechanisms

| Change | Effect |
|--------|--------|
| ↓ Complex I | Impaired oxidative phosphorylation |
| ↑ Glycolysis compensation | Metabolic adaptation |
| ↓ Mitochondrial function | ATP depletion |
| ↑ Oxidative stress | Further damage |

Therapeutic Strategies

| Approach | Rationale |
|----------|-----------|
| Ketogenic diet | Alternative energy |
| Metabolic supplements | Support glycolysis |
| Exercise | Improve metabolism |

Amyotrophic Lateral Sclerosis

Metabolic Dysfunction in ALS

• Hypermetabolism: Increased energy expenditure
• Motor neurons: Vulnerable to metabolic stress
• Astrocytes: Impaired lactate production

Key Findings

| Finding | Implication |
|---------|-------------|
| ↓ Glucose uptake | Energy failure |
| ↑ Resting energy expenditure | Cachexia risk |
| Altered lactate metabolism | ANLS dysfunction |

Huntington's Disease

Metabolism in HD

• 系统性代谢异常: Whole-body metabolic changes
• HTT mutation: Affects energy homeostasis
• 纹状体选择性: Striatal vulnerability

| Change | Brain Region |
|--------|--------------|
| ↓ Glucose metabolism | Striatum, cortex |
| ↑ Lactate | Basal ganglia |
| ↓ PFK | Motor cortex |

Therapeutic Strategies

Current Approaches

Metabolic Enhancers

| Compound | Target | Status |
|----------|--------|--------|
| L-carnitine | Fatty acid oxidation | Clinical trials |
| Alpha-lipoic acid | Mitochondrial function | Research |
| CoQ10 | Electron transport chain | Clinical trials |

Ketogenic Approaches

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Ketogenic diet | Ketone as fuel | Clinical trials |
| Ketone esters | Exogenous ketones | Phase I/II |
| MCT oil | Ketone production | Research |

Glucose Transport Modulation

| Target | Approach | Status |
|--------|----------|--------|
| GLUT1 | Gene therapy | Preclinical |
| GLUT3 | Expression enhancers | Research |
| SGLT2 | Glucose regulation | Research |

Challenges

• Blood-brain barrier penetration
• Metabolic adaptation
• Individual variability
• Long-term safety

Cross-links to Related Pathways

• [PKM2 Metabolic Dysregulation in AD](/mechanisms/pkm2-metabolic-dysregulation-ad)
• [Metabolic Dysfunction in Alzheimer's](/mechanisms/metabolic-dysfunction-alzheimers)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
• [Insulin Signaling in Neurodegeneration](/diseases/neurodegeneration)
• [Type 3 Diabetes Hypothesis](/mechanisms/type-3-diabetes)
• [Ketone Body Metabolism](/mechanisms/dopaminergic-neuron-vulnerability)
• [Astrocyte Reactivity](/mechanisms/astrocyte-reactivity)

See Also

• [Glycolysis](/mechanisms/glycolysis-metabolism-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Brain Metabolism](/mechanisms/dopaminergic-neuron-vulnerability)
• [Glucose Metabolism](/cell-types/glucose-metabolism-vulnerable-neurons)

External Links

• [Glycolysis Pathway - KEGG](https://www.kegg.jp/kegg/pathway/map00010.html)
• [Brain Glucose Metabolism - JCB](https://www.jcb.org)
• [Energy Metabolism in AD - Nature Reviews Neuroscience](https://www.nature.com/nrn)

Background

The study of Glycolysis Metabolism In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

• Liu T et al. (2026 May) [Three-dimensional interactive network: Mitochondrial-metabolic-calcium homeostasis driving Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41659206/). Genes Dis*
• Wang S et al. (2026 May) [Role of glycolysis-mediated histone lactylation in microglial activation and progression of neurodegenerative diseases.](https://pubmed.ncbi.nlm.nih.gov/41577113/). Exp Neurol*
• Yang FG et al. (2026 Apr) [Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications.](https://pubmed.ncbi.nlm.nih.gov/41651180/). Ageing Res Rev*
• Wang Y et al. (2026 Apr) [Shikonin attenuates diabetic Parkinsonian neuronal injury by facilitating p53/SLC25A28-mediated iron shuttling.](https://pubmed.ncbi.nlm.nih.gov/41571207/). Biochem Pharmacol*
• Otu-Boakye S et al. (2026 Apr) [Lipid-laden endothelial cells exhibit a transcriptomic signature linked to blood-brain barrier dysfunction, metabolic reprogramming, and increased inflammation in the aging brain.](https://pubmed.ncbi.nlm.nih.gov/41543825/). Geroscience*

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |

Overall Confidence: 39%

References

Cunnane SC, et al, (2020) (2020)

Mergenthaler P, et al, (2013) (2013)

Pellerin L, Magistretti PJ, (1994) (1994)

Mosconi L, et al, (2008) (2008)

Hertz L, et al, (2015) (2015)

Camandola S, Mattson MP, (2017) (2017)

Zhou Y, et al, (2015) (2015)

Arnold SE, et al, (2018) (2018)

Schön M, et al, (2019) (2019)

Yao J, et al, (2011) (2011)

Pathway Diagram

The following diagram shows the key molecular relationships involving Glycolysis Metabolism in Neurodegeneration discovered through SciDEX knowledge graph analysis: